TherapeuticsMD (TXMD) AI Stock Analysis

• Market Cap: $23.38M
• Dividend Yield: N/A
• Average Volume (3M): 310.58K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: 75.19%
• EPS Growth: N/A
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.05
• Shares Outstanding: 11,574,362
• 10 Day Avg. Volume: 897,126
• 30 Day Avg. Volume: 310,579
• PEG Ratio: 0.45
• Price to Book (P/B): 0.70
• Price to Sales (P/S): 6.24
• P/FCF Ratio: 7.68
• Enterprise Value/Market Cap: 0.91
• Enterprise Value/Revenue: 7.07
• Enterprise Value/Gross Profit: 7.07
• Enterprise Value/Ebitda: -7.07
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.17
• Revenue Forecast (FY): $9.30M

• Rating: 46 Neutral
• Price Target: $2.00 ▲(19.05% Upside)
• Action: Reiterated Date: 03/31/26
• Date: Action: Reiterated 03/31/26

The score is held down primarily by weak financial fundamentals (notably the reported 2025 revenue collapse and ongoing losses), reinforced by bearish technical signals. Offsetting factors include improved cash generation and balance sheet leverage, plus a constructive corporate update showing narrowing losses and growing royalty/license revenue, but valuation support is limited at a ~20.6 P/E with no dividend.

Positive Factors

Improving cash generation

TherapeuticsMD returned to positive operating and free cash flow in 2025, producing $2.45M and improving versus 2024. Sustained positive cash generation provides operational runway, funds strategic alternatives, and reduces near-term financing needs if maintained over several quarters.

Negative Factors

Severe revenue collapse

Revenue falling to zero removes scale economics and undermines any core commercial business. Without meaningful recurring product sales, the company must rely on royalties, one-time transactions, or strategic deals to generate revenue, creating persistent execution risk over months.

TherapeuticsMD Business Overview & Revenue Model

Company Description

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progestero...

Read more

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progestero...

How the Company Makes Money

TherapeuticsMD primarily makes money through licensing-based monetization of its women’s health product assets rather than operating a large in-house commercial sales model. Under this approach, revenue is generated from (1) upfront payments recei...

Read more

TherapeuticsMD primarily makes money through licensing-based monetization of its women’s health product assets rather than operating a large in-house commercial sales model. Under this approach, revenue is generated from (1) upfront payments recei...

TherapeuticsMD Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Mar 2023	Dec 2021
Income Statement
Total Revenue	3.02M	1.76M	1.30M	69.96M	2.57M
Gross Profit	3.02M	1.76M	1.30M	68.57M	1.17M
EBITDA	-3.02M	-2.98M	-8.08M	11.86M	-70.84M
Net Income	-569.00K	-2.18M	-10.28M	112.00M	-172.41M
Balance Sheet
Total Assets	37.66M	38.82M	43.31M	90.46M	169.47M
Cash, Cash Equivalents and Short-Term Investments	7.48M	5.06M	4.33M	38.07M	64.91M
Total Debt	5.12M	7.17M	8.01M	8.76M	197.69M
Total Liabilities	10.78M	11.45M	14.02M	55.31M	263.09M
Stockholders Equity	26.88M	27.37M	29.29M	35.14M	-93.62M
Cash Flow
Free Cash Flow	2.45M	732.00K	0.00	-4.43M	-147.84M
Operating Cash Flow	2.45M	732.00K	-48.14M	-4.08M	-147.81M
Investing Cash Flow	0.00	0.00	0.00	223.48M	-2.22M
Financing Cash Flow	0.00	0.00	3.15M	-235.21M	134.67M

TherapeuticsMD Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.68
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TXMD, the sentiment is Negative. The current price of 1.68 is below the 20-day moving average (MA) of 2.18, below the 50-day MA of 2.25, and above the 200-day MA of 1.59, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 40.83 is Neutral, neither overbought nor oversold. The STOCH value of 34.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TXMD.

TherapeuticsMD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RDHL	47 Neutral	$4.07M	-0.42	―	―	―	―
TXMD	46 Neutral	$23.38M	-33.14	0.27%	―	75.19%	―
AYTU	45 Neutral	$27.58M	-0.62	-107.16%	―	-15.61%	-68.96%
PRPH	42 Neutral	$854.40K	-0.70	-404.42%	―	―	―

TherapeuticsMD Corporate Events